84354 Federal Register / Vol. 85, No. 248 / Monday, December 28, 2020 / Notices 

submits an annual report to the 

Secretary of HHS and to Congress 

describing its activities, including 

findings and recommendations made by 

the ACICBL concerning the activities 

under sections 750–760 of the PHS Act. 

Since priorities dictate meeting times, 

be advised that start times, end times, 

and agenda items are subject to change. 

For CY 2021 meetings, agenda items 

may include, but are not limited to, 

policy and program development and 

other significant matters related to 

activities authorized under Part D of the 

PHS Act as well as issues related to the 

pending Committee reports. Refer to the 

ACICBL website listed above for all 

current and updated information 

concerning the CY 2021 ACICBL 

meetings, including meeting times, draft 

agendas, and meeting materials that will 

be posted 30 calendar days before the 

meeting. 

Members of the public will have the 

opportunity to provide comments. 

Public participants may submit written 

statements in advance of the scheduled 

meeting(s). Oral comments will be 

honored in the order they are requested 

and may be limited as time allows. 

Requests to submit a written statement 

or make oral comments to the ACICBL 

should be sent to Shane Rogers using 

the contact information above at least 5 

business days before the meeting 

date(s). 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Shane 

Rogers using the contact information 

listed above at least 10 business days 

before the meeting(s) they wish to 

attend. 

If a meeting is held in-person, it will 

occur in a federal government building 

and attendees must go through a 

security check to enter. Non-U.S. citizen 

attendees must notify HRSA of their 

planned attendance at an in-person 

meeting at least 20 business days prior 

to the meeting in order to facilitate their 

entry into the building. All attendees are 

required to present government-issued 

identification prior to entry. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2020–28466 Filed 12–23–20; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Findings of research 

misconduct have been made against 

Yihong Wan, Ph.D. (Respondent), 

Associate Professor, Department of 

Pharmacology, University of Texas 

Southwestern Medical Center (UTSMC). 

Respondent engaged in research 

misconduct in research supported by 

U.S. Public Health Service (PHS) funds, 

specifically National Institute of 

Diabetes and Digestive and Kidney 

(NIDDK), National Institutes of Health 

(NIH), grant R01 DK089113. The 

administrative actions, including 

supervision for a period of three (3) 

years, were implemented beginning on 

December 8, 2020, and are detailed 

below. 

FOR FURTHER INFORMATION CONTACT: 

Elisabeth A. Handley, Director, Office of 

Research Integrity, 1101 Wootton 

Parkway, Suite 240, Rockville, MD 

20852, (240) 453–8200. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the Office of Research 

Integrity (ORI) has taken final action in 

the following case: 

Yihong Wan, Ph.D., University of 

Texas Southwestern Medical Center: 

Based on the report of an investigation 

conducted by UTSMC and additional 

analysis conducted by ORI in its 

oversight review, ORI found that 

Respondent, Associate Professor, 

Department of Pharmacology, UTSMC, 

engaged in research misconduct in 

research supported by PHS funds, 

specifically NIDDK, NIH, grant R01 

DK089113. 

ORI found that Respondent engaged 

in research misconduct by intentionally, 

knowingly, and/or recklessly falsifying 

and/or fabricating bone 

histomorphometry data by altering or 

creating Excel data table values for 

additional bone samples that did not 

exist or were not analyzed and by 

falsely stating means and standard 

deviations calculated from experiments 

with N values 

(i.e., number of mouse samples) that 

were larger than the actual N values in 

the following published paper: 

• miR–34a blocks osteoporosis and 

bone metastasis by inhibiting 

osteoclastogenesis and Tgif2. Nature 

2014;512(7515):431–5 (hereafter referred 

to as ‘‘Nature 2014’’). Retraction in: 

Nature 2020 Jun;582(7810):134. 

Specifically, ORI found that 

Respondent knowingly, intentionally, 

and/or recklessly falsified and/or 

fabricated bone histomorphometry data 

in eight (8) extended figures of one (1) 

published paper by manually falsifying 

and/or fabricating data values within 

multiple Excel spreadsheets and by 

creating increased N values without 

testing additional samples. Specifically: 

• In Extended Figure 1i of Nature 

2014, Respondent fabricated female 

vertebrae histomorphometry data by 

multiplying fourteen (14) different 

numerical values representing male 

mouse vertebrae data by a factor of 0.95 

to create female vertebrae values in one 

(1) Excel spreadsheet 

• in Extended Figures 1i, 2d, 3d, 3h, 

4h, 6a, 6e, and 9g of Nature 2014, 

Respondent falsified histomorphometry 

data for ninety-nine (99) data table 

values from two (2) Excel spreadsheets 

representing bone parameters for male 

distal femur, male vertebrae, female 

distal femur, and female vertebrae 

samples 

• in Extended Figure 4h of Nature 

2014, respondent fabricated bone 

histomorphometry data by reporting 

that the means and standard deviations 

were calculated from experiments with 

a value of six (6) to eight (8) mice per 

experimental condition, when 

respondent calculated the means and 

standard deviations from only three (3) 

mice (N = 3) 

Dr. Wan entered into a Voluntary 

Settlement Agreement (Agreement) and 

agreed to the following: 

(1) Respondent agreed to have her 

research supervised for a period of three 

(3) years beginning on December 8, 

2020. Respondent agreed that prior to 

the submission of an application for 

PHS support for a research project on 

which Respondent’s participation is 

proposed and prior to Respondent’s 

participation in any capacity on PHSsupported research, Respondent shall 

ensure that a plan for supervision of 

Respondent’s duties is submitted to ORI 

for approval. The supervision plan must 

be designed to ensure the scientific 

integrity of Respondent’s research 

contribution. Respondent agreed that 

she shall not participate in any PHSsupported research until such a 

supervision plan is submitted to and 

approved by ORI. Respondent agreed to 

maintain responsibility for compliance 

with the agreed upon supervision plan. 

(2) The requirements for Respondent’s 

supervision plan are as follows: 

i. A committee of 2–3 senior faculty 

members at the institution who are 

familiar with Respondent’s field of 

research, but not including 

Respondent’s supervisor or 

collaborators, will provide oversight and 

guidance for a period of three (3) years 

from the effective date of the 

Agreement. The committee will review 

primary data from Respondent’s 

laboratory on a quarterly basis and 

submit a report to ORI at six (6) month 


tkelley on DSKBCP9HB2PROD with NOTICES
Federal Register / Vol. 85, No. 248 / Monday, December 28, 2020 / Notices 84355 

intervals, setting forth the committee 

meeting dates and Respondent’s 

compliance with appropriate research 

standards and confirming the integrity 

of Respondent’s research. 

ii. The committee will conduct an 

advance review of any PHS grant 

applications (including supplements, 

resubmissions, etc.), manuscripts 

reporting PHS-funded research 

submitted for publication, and abstracts. 

The review will include a discussion 

with Respondent of the primary data 

represented in those documents and 

will include a certification to ORI that 

the data presented in the proposed 

application/publication are supported 

by the research record. 

(3) Respondent agreed that for a 

period of three (3) years beginning on 

December 8, 2020, any institution 

employing her shall submit, in 

conjunction with each application of 

PHS funds, or report, manuscript, or 

abstract involving PHS-supported 

research in which Respondent is 

involved, a certification to ORI that the 

data provided by Respondent are based 

on actual experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are 

accurately reported in the application, 

report, manuscript, or abstract. 

(4) If no supervisory plan is provided 

to ORI, Respondent agreed to provide 

certification to ORI at the conclusion of 

the supervision period that she has not 

engaged in, applied for, or had her name 

included on any application, proposal, 

or other request for PHS funds without 

prior notification to ORI. 

(5) Respondent agreed to exclude 

herself voluntarily from serving in any 

advisory capacity to PHS including, but 

not limited to, service on any PHS 

advisory committee, board, and/or peer 

review committee, or as a consultant for 

a period of three (3) years, beginning on 

December 8, 2020. 

Dated: December 21, 2020. 

Elisabeth A. Handley, 

Director, Office of Research Integrity, Office 

of the Assistant Secretary for Health. 

[FR Doc. 2020–28566 Filed 12–23–20; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Biomedical Devices for Ventricular Repair. 

Date: January 22, 2021. 

Time: 10:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Stephanie J Webb, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 208–V, 

Bethesda, MD 20892, (301) 827–7992, 

stephanie.webb@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: December 18, 2020. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28527 Filed 12–23–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of 

meetings of the National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council. 

The meeting will be open to the 

public as indicated below, with a short 

public comment period at the end. The 

open session will be videocast and can 

be accessed from the NIH Videocasting 

and Podcasting website (http://

videocast.nih.gov). 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council. 

Date: September 1–2, 2021. 

Open: September 01, 2021, 10:00 a.m. to 

1:15 p.m. 

Agenda: To present the Director’s Report 

and other scientific presentations. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: September 02, 2021, 1:25 p.m. to 

1:45 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452, Bethesda, 

MD 20892, (301) 594–4757, malikk@

niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council; Digestive Diseases and Nutrition 

Subcommittee. 

Date: September 1–2, 2021. 

Open: September 02, 2021, 10:00 a.m. to 

11:30 a.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: September 02, 2021, 11:45 a.m. to 

1:15 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452, Bethesda, 

MD 20892, (301) 594–4757, malikk@

niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council; Diabetes, Endocrinology and 

Metabolic Diseases Subcommittee. 

Date: September 1–2, 2021. 

Open: September 02, 2021, 10:00 a.m. to 

11:30 a.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 


tkelley on DSKBCP9HB2PROD with NOTICES